Skip to content

Pulmonary local immunity in ANCA associated vasculitis and its correlation with disease recurrence

Pulmonary local immunity in ANCA associated vasculitis and its correlation with disease recurrence

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200064845
Enrollment
Unknown
Registered
2022-10-19
Start date
2022-10-18
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ANCA associated vasculitis

Interventions

Case series:None

Sponsors

Peking Union Medical College Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Diagnosis requires clinical or pathological evidence of vasculitis. Clinical evidence includes: alveolar hemorrhage, pulmonary infiltration, hematuria with RBC casts or heterotypic RBC>10% or hematuria with urinary protein 2+, mononeuritis or polyneuritis, palpable purpura, myocardial infarction caused by coronary vasculitis. Pathological evidence includes necrotizing vasculitis of any organ, necrotizing glomerulonephritis or crescent nephritis, and leukocytoclastic vasculitis. With or without ANCA (+). 2. AAV includes GPA, MPA and EGPA. Their clinical classification criteria refer to the standards of American Association of Rheumatology (ACR) and the consensus of Chapel Hill Conference separately. 3. AAV associated pulmonary involvement, including but not limited to: alveolar hemorrhage, pulmonary interstitial disease, pulmonary infiltration, pulmonary nodule/mass/cavity, large airway or small airway disorders.

Exclusion criteria

Exclusion criteria: 1. Combined with definite infectious lesions. 2. Combined with definite neoplastic lesions. 3. Contraindications to bronchoscopy and bronchoalveolar lavage exist. 4. Unqualified alveolar lavage fluid (recovery volume < 30% of lavage volume; Iatrogenic factors lead to blood recovery fluid). 5. Patients who fail to follow up on schedule.

Design outcomes

Primary

MeasureTime frame
B lymphocyte count in BALF;

Secondary

MeasureTime frame
IL6 concentration in BALF;IL13 concentration in BALF;

Countries

China

Contacts

Public ContactZhang Ting

Peking Union Medical College Hospital

tintin-03@163.com+86 13811583221

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026